VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Monday, highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company announced that its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. The company’s executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations.
The BiTAC platform, which is a registered trademark of VERAXA Biotech GmbH, is designed to generate bispecific T-cell engagers and other antibody-based therapeutics. According to the company, the platform is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The full press release is available at https://ibn.fm/xTF5q. For more information about VERAXA, visit http://ibn.fm/VRXA.
The update comes as the biotech sector sees heightened interest in T-cell engagers and ADCs, which are emerging as promising modalities for cancer treatment. VERAXA’s focus on solid tumors distinguishes it from many competitors that target hematologic malignancies. The company’s ability to secure partnerships could provide non-dilutive funding to support its pipeline advancement.
